SRSF2

Across TCGA pan-cancer cohorts, SRSF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRSF2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SRSF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRSF2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

HNSC, COAD, and LSCC are the cancer types where SRSF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.669	0.911	<.001	43	view →
COAD	DFS	Median	All	1.000	0.886	.020	12	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.656	.006	11	view →
OV	DFS	Median	All	1.000	0.871	.049	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
PDAC	DFS	Tertile	III,IV	0.868	0.622	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRSF2–HNSC (DFS)

Open the HNSC breakdown →